Seald
About[edit]
Seald AS is a Norwegian biotechnology company developing novel therapeutics for bile duct cancer (cholangiocarcinoma). Founded in 2016.
Focus Area[edit]
Bile duct cancer (cholangiocarcinoma) is a rare but aggressive cancer arising from the bile ducts. It is classified as an orphan disease with limited treatment options, particularly for advanced/metastatic disease. The company is developing an entirely new, innovative approach to treating this cancer.
Pipeline[edit]
Seald is developing:
- Technology platform for bile duct cancer
- Novel therapeutic candidates
Organization[edit]
The company has a structured organization including:
- Board of Directors
- Management team
- Advisory Board
- Research partners
- Investor group
Market[edit]
Cholangiocarcinoma (bile duct cancer) affects approximately 200,000 people globally per year. The 5-year survival rate for advanced disease is below 10%, representing significant unmet medical need. Targeted therapies and immunotherapies are active areas of development.